Major clinical research advances in gynecologic cancer in 2017.
- Author:
Dong Hoon SUH
1
;
Miseon KIM
;
Kyung Hun LEE
;
Keun Yong EOM
;
Maj Kamille KJELDSEN
;
Mansoor Raza MIRZA
;
Jae Weon KIM
Author Information
- Publication Type:Review
- Keywords: Poly(ADP-ribose) Polymerase Inhibitors; Molecular Targeted Therapy; Immunotherapy; Ovarian Neoplasms; Breast Neoplasms
- MeSH: Bevacizumab; Brachytherapy; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms, Hereditary Nonpolyposis; Contraception; Drug Therapy; Endometrial Neoplasms; Female; Gynecological Examination; Humans; Immunotherapy; Ligands; Lymph Node Excision; Lymph Nodes; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Radiation Oncology; Receptor, Epidermal Growth Factor; Recurrence; Trastuzumab; Uterine Cervical Neoplasms
- From:Journal of Gynecologic Oncology 2018;29(2):e31-
- CountryRepublic of Korea
- Language:English
- Abstract: In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer. For ovarian cancer, 5 topics were selected including poly(ADP-ribose) polymerases inhibitors and immunotherapy. The other potential practice changers covered in this review were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, incorporation of bevacizumab maintenance in platinum-sensitive recurrent disease, and effect of platinum-free interval prolongation. Conflicting opinions of academic societies on periodic pelvic examination were introduced in conjunction with relevant literature review. For the field of radiation oncology, results of 2 big trials, The Postoperative Radiation Therapy in Endometrial Carcinoma-3 and Gynecologic Oncology Group-258, for endometrial cancer and recent advance in high-dose-rate brachytherapy for cervical cancer were reported. Topics for breast cancer covered adjuvant capecitabine after preoperative chemotherapy, adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive disease, olaparib for metastatic cancer in patients with a germline BRCA mutation, 20-year risks of recurrence after stopping endocrine therapy at 5 years, and contemporary hormonal contraception and the risk of breast cancer.
